Personalized mRNA vaccine from Moderna and Merck halves melanoma recurrence risk over five years
By
Kaitlin Sullivan
Summary
A personalized mRNA vaccine developed by Moderna and Merck has shown in new clinical trial results that it halves the risk of melanoma returning after five years. The findings, presented at the American Society of Clinical Oncology's annual meeting and published in the Journal of Clinical Oncology, offer promising long-term protection against the deadliest form of skin cancer, which recurs in about half of patients within the first five years of treatment.
Source
bskyPersonalized mRNA vaccine from Moderna and Merck halves melanoma recurrence risk over five yearsnbcnews.comKey quotes
· 1 pulledThe treatments we have are not perfect
You might also wanna read
Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up
Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy.
arstechnica.com·4mo ago
Scientists Develop Universal Cancer Vaccine Using mRNA Technology
Scientists have developed a 'universal cancer vaccine' using mRNA technology that can train the immune system to target any type of cancer,
newatlas.com·11mo ago
Programming the immunological properties of mRNA vaccines for cancer
FDA advisory panel unanimously votes to approve Moderna's mRNA flu vaccine after Trump appointee tried to block review
FDA independent advisors voted 9-0 to recommend approval of Moderna's mRNA seasonal flu vaccine (mRNA-1010), despite a Trump appointee at th
arstechnica.com·2d ago
HPV Vaccine at 20: Proven Cancer Prevention Tool Faces Uptake Challenges
The article marks the 20th anniversary of the FDA's approval of the first HPV vaccine in 2006, highlighting its evolution from a quadrivalen
mdsc.pe·4d ago
Long-term HPV vaccine effectiveness study shows stable protection against targeted virus types in Danish women vaccinated as girls
This study examines the long-term effectiveness of HPV vaccination in Danish women who received the 4-valent HPV vaccine as girls in 2008. T
eurosurveillance.org·5mo agoComments
Sign in to join the conversation.
No comments yet. Be the first.